Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Standard Versus Extended Nicotine Patch Therapy for Smoking Cessation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Males and females of descent between the ages of 18-65 who smokes at least 10 cigarettes/day and are seeking smoking cessation treatment.~2. Based on the medical history, physical and laboratory examination, premenopausal female subjects must consent to practice an effective form of contraception during study.~3. Following orientation by the research staff, subjects must sign written informed consent for all study procedures.~Exclusion Criteria:~1. Women who are pregnant, planning a pregnancy, or lactating.~2. Current medical problems for which TN is contraindicated including allergy to nicotine, uncontrolled hypertension, unstable angina, serious arrhythmia, heart attack or stroke within the past 6 months, liver and/or kidney failure in the last 6-months and current diabetes.~3. Current treatment of cancer or diagnosed with cancer in the past 6 months~4. Current DSM IV substance use disorders (dependence involving alcohol, cocaine, marijuana or stimulants, benzodiazepines).~5. Current use of TN or other forms of NRT.~6. Concomitant medications (e.g., monoamine oxidase inhibitors or benzodiazepines within past 14 days, antipsychotics, endogenous steroids, and antidepressants (including wellbutrin or bupropion).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Extended Patch Treatment (Type: EXPERIMENTAL): Participants in this treatment arm receive 24 weeks of 21mg nicotine patch in addition to 8 smoking cessation counseling sessions.
- Standard Patch Treatment (Type: ACTIVE_COMPARATOR): Participants receive 8 weeks of 21mg nicotine patch followed by 16 weeks of placebo patch.

Based on this trial design, predict the completion outcome and termination type (if applicable).